CL2011002913A1 - Plasmido novedoso con numero de acceso mtcc 5561; virus de vaccinia ankara modificado (mva) recombinante. - Google Patents

Plasmido novedoso con numero de acceso mtcc 5561; virus de vaccinia ankara modificado (mva) recombinante.

Info

Publication number
CL2011002913A1
CL2011002913A1 CL2011002913A CL2011002913A CL2011002913A1 CL 2011002913 A1 CL2011002913 A1 CL 2011002913A1 CL 2011002913 A CL2011002913 A CL 2011002913A CL 2011002913 A CL2011002913 A CL 2011002913A CL 2011002913 A1 CL2011002913 A1 CL 2011002913A1
Authority
CL
Chile
Prior art keywords
mva
accession number
modified vaccinia
vaccinia ankara
recombinant modified
Prior art date
Application number
CL2011002913A
Other languages
English (en)
Inventor
Rajesh Jain
Virender Kumar Vinayak
Nidhi Shukla
Neeraj Aggarwal
Rajan Mehta
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CL2011002913A1 publication Critical patent/CL2011002913A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Plásmido novedoso con número de acceso mtcc 5561; virus de vaccinia ankara modificado (mva) recombinante.
CL2011002913A 2009-05-18 2011-11-18 Plasmido novedoso con numero de acceso mtcc 5561; virus de vaccinia ankara modificado (mva) recombinante. CL2011002913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1015DE2009 2009-05-18

Publications (1)

Publication Number Publication Date
CL2011002913A1 true CL2011002913A1 (es) 2012-04-20

Family

ID=43125819

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002913A CL2011002913A1 (es) 2009-05-18 2011-11-18 Plasmido novedoso con numero de acceso mtcc 5561; virus de vaccinia ankara modificado (mva) recombinante.

Country Status (13)

Country Link
US (1) US20120141525A1 (es)
EP (2) EP2432503A4 (es)
JP (1) JP2012527232A (es)
KR (1) KR20120096874A (es)
CN (1) CN102740880A (es)
AR (1) AR076690A1 (es)
AU (1) AU2010250780A1 (es)
BR (1) BRPI1011034A2 (es)
CA (1) CA2762044A1 (es)
CL (1) CL2011002913A1 (es)
EA (1) EA201171436A1 (es)
MX (1) MX2011012312A (es)
WO (1) WO2010134094A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
US9173933B2 (en) 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
CN102140441B (zh) * 2010-11-04 2013-12-18 高福 基于减毒痘苗病毒天坛株为载体的禽流感疫苗
WO2012085936A2 (en) 2010-12-20 2012-06-28 Panacea Biotech Ltd Recombinant respiratory syncytial virus plasmids and vaccines
JP6169494B2 (ja) 2011-01-31 2017-07-26 ナノセラピューティクス・インコーポレイテッドＮａｎｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法
CN102653771B (zh) * 2011-10-29 2014-10-29 上海师范大学 谷氨酰胺转运蛋白1融合蛋白表达载体的应用
US9463238B2 (en) * 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
US11596683B2 (en) 2016-07-12 2023-03-07 Duke University Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same
WO2020163768A1 (en) * 2019-02-07 2020-08-13 Duke University Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
KR102334320B1 (ko) * 2019-11-08 2021-12-03 서울대학교산학협력단 Ｈ９ｎ２ 재조합 인플루엔자 바이러스, 이의 제조용 조성물, 및 이를 포함하는 백신 조성물
KR102277089B1 (ko) * 2019-12-19 2021-07-14 에스케이바이오사이언스(주) A형 간염 바이러스의 제조방법 및 상기의 방법에 따라 제조된 a형 간염 바이러스
CN111926043A (zh) * 2020-08-10 2020-11-13 中国农业科学院兰州兽医研究所 共表达fmdv和pprv抗原基因重组病毒的构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
CN101103103A (zh) * 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
CA2638815A1 (en) * 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods

Also Published As

Publication number Publication date
EP2550974A2 (en) 2013-01-30
EA201171436A1 (ru) 2012-04-30
JP2012527232A (ja) 2012-11-08
CN102740880A (zh) 2012-10-17
EP2432503A4 (en) 2013-01-23
WO2010134094A9 (en) 2011-02-03
AU2010250780A1 (en) 2012-01-12
EP2550974A3 (en) 2013-05-08
MX2011012312A (es) 2011-12-16
EP2432503A1 (en) 2012-03-28
US20120141525A1 (en) 2012-06-07
WO2010134094A1 (en) 2010-11-25
BRPI1011034A2 (pt) 2016-03-15
AR076690A1 (es) 2011-06-29
KR20120096874A (ko) 2012-08-31
CA2762044A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
DK2488649T3 (da) Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder
BR112019024813A2 (pt) adenovírus recombinantes portando transgenes
UA103316C2 (uk) Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
IN2012DN02073A (es)
EA201390866A1 (ru) Филовирусные вакцины на основе аденовирусов серотипа 26 и серотипа 35
UA111603C2 (uk) Електродний вузол вакуумного вимикача
CL2007002182S1 (es) Terminal.
EA201100084A1 (ru) Сшиваемая полимерная композиция
EA201290300A1 (ru) Сшиваемая полимерная композиция и кабель с улучшенными электрическими свойствами
MX2014014024A (es) Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
UA107822C2 (xx) Визначені триазолопіридини та триазолопіразини, їх композиції та їх застосування
ECSP10010288A (es) Vectores de virus oncolíticos de viruela
BRPI0919696A2 (pt) Polipeptídeo substancialmente purificado, microorganismo recombinante, e, polinucleotídeo isolado.
EP2432503A4 (en) BASED ON RECOMBINANTLY MODIFIED VACCINIA ANKARA VIRUS UNIVERSAL GRIP VACCINATE
NZ608143A (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
MX2010010457A (es) Vectores recombinantes de rinovirus.
MY153917A (en) Tsp-1, tsp-2, il-17br and hb-egf associated with stem cell activities and applications thereof
MX2015012905A (es) Formulaciones de factor viii recombinantes.
MA38294B1 (fr) Plaque d'amortissement réfractaire
MX2009000898A (es) Metodos y composiciones para aumentar el tropismo en tejido de vectores adenovirales recombinantes.
IL291352A (en) Grenade with independently detachable segments
WO2008118936A3 (en) Method of elicting immune response with a modified mva viral hiv-1 vector